Stocksigma LogoStocksigma Logo

Remus Pharmaceuticals H1-FY27 Financial and Operational Performance Overview

Remus Pharmaceuticals delivered a strong H1-FY27 consolidated performance, with operational revenue rising 53.4% YoY to INR 6,141 Mn, EBITDA increasing

Remus Pharmaceuticals H1-FY27 Financial and Operational Performance Overview

Remus Pharmaceuticals Ltd 路 Investor Presentation 路 04 Nov 2026, 5:32 pm

Remus Pharmaceuticals H1-FY27 Financial and Operational Performance Overview Remus Pharmaceuticals delivered a strong H1-FY27 consolidated performance, with operational revenue rising 53.4% YoY to INR 6,141 Mn, EBITDA increasing 11.2% YoY to INR 299 Mn, and PAT growing 14.4% YoY to INR 247 Mn. Standalone revenue and PAT grew 32.4% and 56.7% YoY to INR 621 Mn and INR 188 Mn, respectively. The company expanded its pipeline to 955+ approved products across 2,443+ global registrations and dossiers, won a 24-product tender in Bolivia, obtained Peruvian Digemid plant approval, and secured approval for Semaglutide formulations.

Original exchange filing (PDF)

More announcements from Remus Pharmaceuticals Ltd

All Remus Pharmaceuticals Ltd announcements